Trial Profile
B-cell Depletion Therapy With Rituximab for Thyroid Eye Disease
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Rituximab (Primary) ; Methylprednisolone sodium succinate
- Indications Graves ophthalmopathy
- Focus Therapeutic Use
- Acronyms BetTeRTED
- 14 Nov 2019 Status changed from recruiting to discontinued.
- 07 Jun 2019 Planned End Date changed from 1 Jul 2019 to 1 Dec 2019.
- 07 Jun 2019 Planned primary completion date changed from 1 Jul 2019 to 1 Dec 2019.